Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation

Autor: A. T. Portman, V. Sturm, Michiel J. Staal, RP Maguire, L. Burghaus, Klaus L. Leenders, A. Koulousakis, Karl Herholz, Wolf-Dieter Heiss, Rüdiger Hilker, Jan Pruim, T. van Laar, J. Voges, B. M. de Jong
Přispěvatelé: Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Jazyk: angličtina
Rok vydání: 2005
Předmět:
Oncology
Male
Paper
medicine.medical_specialty
Pathology
Deep brain stimulation
Parkinson's disease
medicine.medical_treatment
Deep Brain Stimulation
METABOLISM
Neuroprotection
Receptors
Dopamine
Central nervous system disease
Degenerative disease
POSITRON-EMISSION-TOMOGRAPHY
Subthalamic Nucleus
Internal medicine
medicine
Humans
Prospective Studies
Aged
ECAT EXACT
business.industry
Putamen
Parkinson Disease
Middle Aged
PERFORMANCE
medicine.disease
F-18 DOPA-PET
EVOLUTION
nervous system diseases
Functional imaging
Psychiatry and Mental health
Subthalamic nucleus
Editorial Commentary
SCANNER
surgical procedures
operative
nervous system
Positron-Emission Tomography
Disease Progression
HIGH-FREQUENCY STIMULATION
Surgery
Female
Neurology (clinical)
business
FOLLOW-UP
therapeutics
DEEP BRAIN-STIMULATION
Zdroj: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 76(9), 1217-1221. BMJ PUBLISHING GROUP
ISSN: 0022-3050
Popis: Objectives: Glutamate mediated excitotoxicity of the hyperactive subthalamic nucleus (STN) has been reported to contribute to nigral degeneration in Parkinson's disease (PD). Deep brain stimulation of the STN (STN DBS), in its role as a highly effective treatment of severe PD motor complications, has been. thought to inhibit STN hyperactivity and therefore decrease progression of PD.Methods: In a prospective two centre study, disease progression was determined by means of serial F-18-fluorodopa (F-dopa) positron emission tomography (PET) in 30 patients with successful STN DBS over the first 16 (SD 6) months after surgery.Results: Depending on the method of PET data analysis used in the two centres, annual progression rates relative to baseline were 9.5-12.4% in the caudate and 10.7-12.9% in the putamen.Conclusions: This functional imaging study is the first to demonstrate a continuous decline of dopaminergic function in patients with advanced PD under clinically effective bilateral STN stimulation. The rates of progression in patients with STN DBS were within the range of previously reported data from longitudinal imaging studies in PD. Therefore this study could not confirm the neuroprotective properties of DBS in the STN target.
Databáze: OpenAIRE
Externí odkaz: